New RSV vaccine for older adults can result in individual and societal cost savings, benefits

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

from Latest Science News -- ScienceDaily https://ift.tt/lNbpoO3